Summary
Plasma levels of lipoprotein-a [Lp(a)] >30 mg/dl represent an independent risk factor for cardiovascular diseases with both proatherosclerotic and prothrombotic activity. The results of dietary or pharmacological treatment are not encouraging and are often controversial. We have evaluated a combination of medical treatment with Gemfibrozil (600 mg bid) and a Mediterranean diet for 2 months in 15 patients with both hypercholesterolemia (>240 mg/dl) and high levels of Lp(a) (>30 mg/dl). Three patients dropped out within the first 2 weeks, complaining of epigastric pain and burning; the remainder (5 females and 7 males, mean age 70 years) completed the treatment without any side effects. The median values of Lp(a) decreased from 36.5 to 8.4 mg/dl (p<0.0002) and total cholesterol from 254.5 to 208.0 mg/dl (p<0.0001). The small number of patients does not permit any definitive conclusion on effectiveness to be drawn, but the results indicate further randomized studies might prove worthwhile.
Similar content being viewed by others
References
Scanu AM, Fless GM. Lipoprotein (a)—Heterogeneity and biological relevance.J Clin Invest 1990;85:1709–1715.
Edelberg JM, Pizzo SV. Lipoprotein (a): The link between impaired fibrinolysis and atherosclerosis.Fibrinolysis 1991;5:135–143.
Tyrrell J, Cooke T, Reilly M, et al. Lipoprotein [Lp(a)] and peripheral vascular disease.J Intern Med 1992;232:349–352.
Fidanza F. The Mediterranean Italian diet: Keys to contemporary thinking.Proc Nutr Soc 1991;50:519–526.
Hunninghake DB. Drug treatment of dyslipoproteinemia.Endocrinol Metab Clin North Am 1990;19:345–360.
Levine DM, Parker TS, Sloan BJ. Automated measurement of Lp(a) by immunoturbidimetric analysis.Int J Clin Lab Res 1992;22:173–178.
Boyer H, de Gennes JL, Truffert J, et al. Lp(a) levels in different types of dyslipidaemia in the French population.Atherosclerosis 1990;85:61–69.
Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a).Atherosclerosis 1982;44:61–71.
Kostner GM, Gavish D, Leopold B, et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.Circulation 1989;80:1313–1319.
Slunga L, Johnson O, Dahlen GH. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.Eur J Clin Pharmacol 1992;43:369–373.
Leren TP, Hjermann I, Foss OP, et al. Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein (a) level in familial hypercholesterolemic subjects.Clin Invest 1992;70:711–718.
Gurakar AJ, Hoeg JM, Kostner GM, et al. Levels of lipoprotein (a) decline with neomycin and niacin treatment.Atherosclerosis 1985;57:293–301.
Beil FU, Terres W, Orgass M, Greten H. Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia.Atherosclerosis 1991;90:95–97.
Gavish D, Breslow JL. Lipoprotein (a) reduction by N-acetylcysteine.Lancet 1991;337:203–204.
Scanu AM. N-acetylcysteine and immunoreactivity of lipoprotein(a) [letter].Lancet 1991;337:1159.
Frick MH, Elo O, Haapa K, Heinonen OP, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.N Engl J Med 1987;317:1237–1245.
Jones PH, Gotto AM, Pownall HJ, et al. Effect of gemfibrozil on plasma lipoprotein (a) levels in type IIa hyperlipoproteinemic subjects.Circulation 1991;84(Suppl):II483.
Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone or in combination for the treatment of hypercholesterolemia.Am J Med 1993;94:13–20.
Bimmermann A, Boerschmann C, Schartzkopff W, Von Baeyer H, Schleicher J. Effective therapeutic measures for reducing lipoprotein(a) in patients with dyslipidemia. Lipoprotein(a) reduction with sustained-release bezafibrate.Curr Ther Res 1991;49:635–643.
Maggi FM, Biasi GM, Catapano AL. Reduction of Lp(a) plasma levels by bezafibrate.Atherosclerosis 1993;100:127–128.
Julius U, Hora C, Gross P, Fucker K, Bergmann S, Hanefeld M. Different effects of fibrates on lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types. of hyperlipoproteinemia.Fortschr Med 1992;110:669–672.
Thorogood M, Roe L, McPherson K, Mann J. Dietary intake and plasma lipid levels: Lessons from a study on the diet of health conscious group.Br Med J 1990;300:1297–1301.
Singh RB, Rastogi SS, Verma R, Laxami B, Singh R, Ghosh S. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: Results of one year follow-up.Br Med J 1992;304:1015–1019.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Simoni, G., Gianotti, A., Ardia, A. et al. Gemfibrozil and mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol—Pilot study. Cardiovasc Drug Ther 9, 347–350 (1995). https://doi.org/10.1007/BF00878680
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00878680